GlassScriptPhysician profile
Ronald S Murray
NPI 1164484309
$121,186.85
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $19K · 2021: $13K · 2022: $217.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $72,963.36 | 2019-2022 | |
| Genzyme Corporation | $47,363.39 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $367.01 | 2019-2022 | |
| Emd Serono, INC. | $227.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $146.15 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $23.42 | 2019 | |
| Amgen INC. | $22.40 | 2020 | |
| Acorda Therapeutics, INC | $21.79 | 2019 | |
| Akcea Therapeutics, INC. | $20.17 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.54 | 2019 | |
| Sk Life Science, INC. | $14.36 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.